Analyst Ratings For Genedrive PLC (LON:GDR)
Today, Peel Hunt reiterated its Buy rating on Genedrive PLC (LON:GDR).
There are 1 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Genedrive PLC (LON:GDR) is Buy with a consensus target price of GBX 152 per share, a potential .
Some recent analyst ratings include
- 8/8/2018-Peel Hunt Reiterated Rating of Buy.
About Genedrive PLC (LON:GDR)
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. It operates through three divisions: Preclinical Research Services, Pharmacogenomic Services, and Diagnostics. The Preclinical Research Services division provides pre-clinical testing services in the areas of oncology, oncology supportive care, inflammatory bowel disease, leukaemia, gastrointestinal disease, inflammation, skin care and wound healing, and rheumatoid arthritis. The Pharmacogenomic Services division offers molecular measures of biological processes. The Diagnostics division is involved in commercializing the Genedrive point of need molecular testing platform. It serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is based in Manchester, the United Kingdom.
Recent Trading Activity for Genedrive PLC (LON:GDR)
Shares of Genedrive PLC closed the previous trading session at 31.80 up +1.30 4.26% with shares trading hands.
